Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455898 | 1.00 | LMNA (0.33) | LMNAALDH1A1TDP1L3MBTL1 | |
| SCHEMBL15043912 | 0.83 | — | — | |
| SCHEMBL18401129 | 0.83 | TSHR (0.32) | TDP1 | |
| SCHEMBL1318748 | 0.81 | LMNA (0.38) | LMNAALDH1A1 | |
| SCHEMBL17467940 | 0.79 | FDPS (0.30) | — | |
| SCHEMBL2829020 | 0.75 | TDP1 (0.35) | LMNAALDH1A1TDP1 | |
| SCHEMBL15280843 | 0.75 | TDP1 (0.35) | LMNAALDH1A1TDP1 | |
| SCHEMBL12187328 | 0.75 | TSHR (0.48) | — | |
| SCHEMBL28047184 | 0.75 | THRB (0.30) | LMNAALDH1A1 | |
| SCHEMBL29212752 | 0.72 | LMNA (0.38) | LMNAALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291567-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | GFBIOCHEMICALS LIMITED (MT) | 2015-10-15 | — | — | US | disclosed |
| US-20140135455-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8653223-B2 | Transketalized compositions, synthesis, and applications | SEGETIS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8546519-B2 | Polyketal compounds, synthesis, and applications | SEGETIS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110021658-A1 | Polyketal Compounds, Synthesis, and Applications | SEGETIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2205606-A2 | POLYKETAL COMPOUNDS, SYNTHESIS, AND APPLICATIONS | Segetis, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009146202-A2 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009049041-A2 | POLYKETAL COMPOUNDS, SYNTHESIS, AND APPLICATIONS | SEGETIS, INC. (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021658-A1 | Polyketal Compounds, Synthesis, and Applications | TKT, KYAT1, KHK | LMNA 1688/4885ALDH1A1 1918/4885TDP1 2481/4885 |
| US-20140135455-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | LMNA 1269/4885ALDH1A1 2261/4885TDP1 2292/4885 |
| US-20110082264-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | LMNA 1269/4885ALDH1A1 2261/4885TDP1 2292/4885 |
| US-20150291567-A1 | TRANSKETALIZED COMPOSITIONS, SYNTHESIS, AND APPLICATIONS | TKT, KHK, KYAT3 | LMNA 1269/4885ALDH1A1 2261/4885TDP1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.